Alpha Centric Advisors LLC Morpho Sys Ag Transaction History

Alpha Centric Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	BUY	$4.14 - $22.13 $163,530 - $874,135	39,500 Added 27.15%	185,000 $931,000
Q4 2021 Feb 25, 2022	BUY	$9.08 - $12.45 $404,060 - $554,025	44,500 Added 44.06%	145,500 $1.37 Million
Q3 2021 Mar 09, 2022	BUY	$11.76 - $19.51 $652,680 - $1.08 Million	55,500 Added 121.98%	101,000 $1.19 Million
Q2 2021 Mar 09, 2022	BUY	$18.95 - $23.95 $502,175 - $634,675	26,500 Added 139.47%	45,500 $876,000
Q1 2021 Mar 09, 2022	BUY	$21.56 - $30.66 $297,528 - $423,108	13,800 Added 265.38%	19,000 $414,000

Q4 2020 Mar 11, 2022	BUY	$24.81 - $30.33 $129,012 - $157,716	5,200 New	5,200 $147,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.